agalsidase alfa Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	5021	None

Description:

Molecule	Description
Synonyms: agalsidase alfa replagal agalsidase alfa (genetical recombination)	genetically engineered, glycosylated human alpha-galactosidase isoenzyme A used in treatment of Fabry disease Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
1	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 3, 2001	EMA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

Source	Code	Description
ATC	A16AB03	ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Enzymes

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Fabry's disease	indication	16652001	DOID:14499

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
globotriaosylceramide (GL-3)	Metabolite			HYDROLYTIC ENZYME				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
2HLC17MX9G	UNII
D02784	KEGG_DRUG
104138-64-9	SECONDARY_CAS_RN
C0962517	UMLSCUI
CHEMBL2108214	ChEMBL_ID
DB15874	DRUGBANK_ID
8048	INN_ID
C000627036	MESH_SUPPLEMENTAL_RECORD_UI
008578	NDDF
423634009	SNOMEDCT_US
424905009	SNOMEDCT_US

Pharmaceutical products:

None